tbuckley/cabot-search huggingface dataset:
Consolidating Memories
Authors: Carolyn J. Hildreth
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diabetes and Cardiovascular Disease
Authors: William B. Kannel
Journal: JAMA (1979)

Based on 20 years of surveillance of the Framingham cohort relating subsequent cardiovascular events to prior evidence of diabetes, a twofold to threefold increased risk of clinical atherosclerotic disease was reported. The relative impact was greatest for intermittent claudication (IC) and congestive heart failure (CHF) and least for coronary heart disease (CHD), which was, nevertheless, on an absolute scale the chief sequela. The relative impact was substantially greater for women than for men. For each of the cardiovascular diseases (CVD), morbidity and mortality were higher for diabetic women than for nondiabetic men. After adjustment for other associated risk factors, the relative impact of diabetes on CHD, IC, or stroke incidence was the same for women as for men; for CVD death and CHF, it was greater for women. Cardiovascular mortality was actually about as great for diabetic women as for diabetic men. (<i>JAMA</i>241:2035-2038, 1979)
Hypokalemia
Authors: Edward Jones
Journal: New England Journal of Medicine (2004)

Choices about Meningococcal Vaccinationto the editor: The recommendation by Offit and Peter in their Sounding Board article (Dec.11 issue) 1 that clinicians and colleges actively inform parents about the benefits of meningococcal vaccine is a classic example of the "fallacy of the commons."The fallacy is that individuals can act without consequences to themselves or society.For example, the authors seem to assume that a parent's decision to purchase $80 of vaccine will incur no loss of opportunity to purchase something more valuable, such as a lipid profile.They seem to assume that the effort spent on informing parents of college students about the meningococcal vaccine will not affect the ability to inform them of more pressing issues, such as alcohol abuse.They assume that the time devoted by a student health service to a visit for meningococcal vaccine will not preclude attention to another college student who has a real problem.They also assume that meningococcal vaccination is the only rare risk worthy of such notification (what about tuberculosis or lightning strikes?).Everything we do consumes resources of time, money, effort, and opportunity.
Phase I study of the combination of everolimus (RAD001) with panitumumab in patients with refractory solid malignancies.
Authors: J. M. Davies, L. L. Raftery, H. K. Sanoff, T. Triglianos, K. Keller, A. Ivanova, S. A. Bernard, R. M. Goldberg, E. C. Dees, B. H. O'Neil
Journal: Journal of Clinical Oncology (2010)

e13085 Background: EGFR activation results in downstream activation of the PI3K/AKT/mTOR axis. It is plausible that inhibition of mTOR with the inhibitor everolimus will further improve activity of chemotherapy plus an EGFR antibody. Purpose: This phase I study is to determine the maximum tolerated doses (MTD) and the safety of everolimus combined with panitumumab in patients with solid tumors refractory to therapy. Simultaneous evaluation of everolimus with 5FU/LV is ongoing. Methods: A standard 3+3 design was used with panitumumab starting at 3.6 mg/kg q2weeks given with everolimus 50 mg weekly. Everolimus dosing was changed to daily after dose level 2 because of mouth ulcers and has been escalated to 5 mg daily. Further dose escalation is planned, to panitumumab 6 mg/kg q2weeks with everolimus 10 mg daily. Dose-limiting toxicities (DLT) were assessed in cycle 1 (4 weeks), defined as any grade 3/4 nonhematologic toxicity (with the exception of gr 3 skin rash, nausea and diarrhea), ANC <0.5 x 109 cells/L lasting more than 7 days or associated with fever or infection, or platelets <25 x 109 cells/L of any duration or <50 x 109 cells/L with major bleeding. Tumors were assessed every 8 weeks. Results: Between 03/2008 and 11/2009, 18 patients were treated. Median age 59 (range 41-77), male/female 10/8, PS 0/1/2 of 7/7/1. At dose level 1, 1/6 patients experienced DLT (gr 4 thrombocytopenia) and 0/3 at dose level 2. Due to high frequency of gr 2 but intolerable mouth ulcer events on weekly dosing, the trial was amended to daily everolimus dosing. At dose level 3, 1/7 had DLT (gr 3 transaminitis) and another patient had rapid disease progression within 1 week of consent and was not evaluable. At dose level 4 (everolimus 5 mg daily), no DLT reported (0/2) and this arm continues to accrue. Up to 4 further dose escalations are anticipated. Responses are as follows: 5 SD and 11 PD. Conclusions: The MTD of everolimus with panitumumab has not yet been reached, but the combination has been tolerable with daily everolimus dosing. Enrollment is expected to be complete by the time of the meeting; data will be updated at that time. Ongoing parallel studies will evaluate the safety and efficacy of this regimen as well as dosing and safety with FOLFOX. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Novartis Amgen, Novartis
Candida fungemia diagnosed from peripheral blood smear
Authors: A. L. Buchman
Journal: JAMA (1988)

Primary catheter sepsis is a serious consequence of the use of indwelling catheters.<sup>1</sup><i>Candida</i>fungi have been the most frequent nonbacterial organisms causing sepsis under these conditions.<sup>1-3</sup><i>Primary catheter sepsis</i>is defined as sepsis in which no other sources of infection can be documented; the fever resolves following catheter removal, and catheter tip culture results are identical to those of the peripheral blood.<sup>4</sup>We describe a case where diagnosis of catheter-related<i>Candida</i>fungemia was diagnosed almost immediately from the peripheral blood smear, compared with the most rapid culture system available, an isolator lysis centrifugation system, which has a mean time to detection of 2.95 days.<sup>5</sup> A 72-year-old woman had a Hickman catheter placed for long-term total parenteral nutrition. Eight days later she became febrille (temperature to 40°C), with chills and rigor. She had a white blood cell count of 12 × 10<sup>9</sup>/L, including 77%
Prognostic Disclosure
Authors: Michael GuntherMaher
Journal: Annals of Internal Medicine (2002)

Letters3 September 2002Prognostic DisclosureMichael GuntherMaher, MDMichael GuntherMaher, MDElder Care, Kaiser-Permanente; Sacramento, CA 95825Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The poignancy of the article by Lamont and Christakis (1) is that it reaches to the boundaries of where science can take us. Physicians sometimes prefer to misrepresent the truth, and no prognostic algorithm will be able to tell us why. I believe the problem cannot be approached without coming to terms with the dissociative process physicians undergo in their selection and training as scientists. We are taught neither to nurture our humanity nor to call on it as a recourse for approaching our patients. We are encouraged to rely on scientific methods, statistical verification, and “evidence-based” ...References1. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001;134:1096-105. [PMID: 11412049] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Elder Care, Kaiser-Permanente; Sacramento, CA 95825 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPrognostic Disclosure to Patients with Cancer near the End of Life Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure James R. Webster Jr. Prognostic Disclosure David Grossman Prognostic Disclosure David Grossman Prognostic Disclosure James R. Webster Jr. Prognostic Disclosure Elizabeth B. Lamont and Nicholas A. Christakis Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: 368KeywordsAlgorithmsArtificial intelligenceDisclosureHealth careScientistsStatistical methods ePublished: 3 September 2002 Issue Published: 3 September 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A Course in Qualitative Inorganic Chemistry.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CARDI-O-METER
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Wood's Medical and Surgical, Monographs.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safeguarding Motherhood
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ORIGINAL INVESTIGATIONS ON THE NATURAL HISTORY, (SYMPTOMS AND PATHOLOGY) OF YELLOW FEVER. 1854-1894.
Authors: JOSEPH JONES
Journal: JAMA (1895)

<h3>Chapter V.</h3> It will be observed that Dr. Dowler records three cases in which in the primary stage of yellow fever, the temperature of the axilla reached 106 degrees; one 106.5 degrees, and one 107 degrees; in the middle period, one case 106 degrees, two cases 107 degrees, one case 108 degrees, one case 108.5 degrees, and one case 109 degrees; and notwithstanding the high temperatures the patients recovered. The patient whose temperature reached 108 was cured in seven days; the one with a temperature of 108.5, was convalescent on the third day; and the third with the axillary temperature at 109 degrees, was cured in twelve days. The highest temperature observed by Dr. Dowler in fatal cases of yellow fever was 110.5 degrees axilla. On the other hand, by boldly exploring the regions of the body, a few moments after death, Dr. Dowler has shown that the temperature of
Nephrology
Authors: L. B. Berman
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Some Aspects Of Language Processing Revealed Through The Analysis Of Acquired Aphasia: The Lexical System
Authors: A Caramazza
Journal: Annual Review of Neuroscience (1988)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome
Authors: Graciela I. Dran, Gabriela C. Fernandez, Carolina J. Rubel, Emilse Bermejo, Sonia Gomez, Roberto Meiss, Martin A. Isturiz, Marina S. Palermo
Journal: Kidney International (2002)

Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome.BackgroundNitric oxide (NO) is an endogenous vasodilator and platelet inhibitor. An enhanced NO production has been detected in patients with hemolytic uremic syndrome (HUS), although its implication in HUS pathogenesis has not been clarified.MethodsA mouse model of Shiga toxin 2 (Stx2)-induced HUS was used to study the role of NO in the development of the disease. Modulation of L-arginine-NO pathway was achieved by oral administration of NO synthase (NOS) substrate or inhibitors, and renal damage, mortality and platelet activity were evaluated. The involvement of platelets was studied by means of a specific anti-platelet antibody.ResultsInhibition of NO generation by the NOS inhibitor L-NAME enhanced Stx2-mediated renal damage and lethality; this effect was prevented by the addition of L-arginine. The worsening effect of L-NAME involved enhanced Stx2-mediated platelet activation, and it was completely prevented by platelet depletion.ConclusionsNO exerts a protective role in the early pathogenesis of HUS, and its inhibition potentiates renal damage and mortality through a mechanism involving enhanced platelet activation. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Nitric oxide (NO) is an endogenous vasodilator and platelet inhibitor. An enhanced NO production has been detected in patients with hemolytic uremic syndrome (HUS), although its implication in HUS pathogenesis has not been clarified. A mouse model of Shiga toxin 2 (Stx2)-induced HUS was used to study the role of NO in the development of the disease. Modulation of L-arginine-NO pathway was achieved by oral administration of NO synthase (NOS) substrate or inhibitors, and renal damage, mortality and platelet activity were evaluated. The involvement of platelets was studied by means of a specific anti-platelet antibody. Inhibition of NO generation by the NOS inhibitor L-NAME enhanced Stx2-mediated renal damage and lethality; this effect was prevented by the addition of L-arginine. The worsening effect of L-NAME involved enhanced Stx2-mediated platelet activation, and it was completely prevented by platelet depletion. NO exerts a protective role in the early pathogenesis of HUS, and its inhibition potentiates renal damage and mortality through a mechanism involving enhanced platelet activation.
Iron deficiency in healthy young college women
Authors: D. E. Scott
Journal: JAMA (1967)

The iron stores of 114 white college women who had never experienced abnormal bleeding nor been pregnant were evaluated using marrow stainable iron and in some instances quantitative phlebotomy. Even though the subjects were somewhat privileged socioeconomically, iron stores were scant to absent in two thirds of them. After being made anemic by repeated phlebotomy, the anemia was corrected at a very slow rate by iron absorbed from their diet. Consequently iron in an effective dose and form should be administered to women who have anemia and iron deficiency or who are hemorrhaging.
Roger Blamey
Authors: N. Stafford
Journal: BMJ (2014)

To determine whether children requiring special education represent a high-risk group for identifying Tourette9s syndrome (TS), we performed direct examinations for the presence of tics in 35 special education and 35 regular classroom students from a single school district. Of the special education students, nine (26%) had definite or probable tics as compared with only two (6%) of the regular classroom students. About one-third of the students with tics currently meet diagnostic criteria for TS and probably more will do so in the future. About one-half of the subjects with tics have evidence of obsessive-compulsive behavior (OCB) or an attention-deficit hyperactivity disorder (ADHD). For three randomly selected students with definite tics, direct examinations of first-degree relatives revealed the presence of tics in all families. Subject to the limitations of this pilot study, we conclude that TS and related tic disorders are commonly associated with the need for special education in this single school district. TS might also be an important contributor to school problems in the childhood population at large and may be a highly prevalent condition. In addition, we conclude that childhood tics are associated with OCB and ADHD, are genetically determined, and are part of the TS clinical spectrum.
Changing distribution of primary cancers in the large bowel
Authors: J. B. Rhodes
Journal: JAMA (1977)

Analysis of the changing distribution of origin site of 1,990 colorectal cancers observed at a large midwestern hospital shows a statistically significant trend of a decreasing percentage of distal (rectum,<i>P</i>=.0192) and an increasing percentage of proximal (cecum,<i>P</i>=.0015) large-bowel lesions during a period of at least 30 years. Mortality data for 11,635 colorectal cancers in the state of Kansas for this period confirm this trend (<i>P</i>&lt;.0001). The respective decrease and increase may well be the result of more than one factor. Results of digital examination of the rectum and sigmoidoscopy are less likely to diagnose large-bowel cancer as they did 30 years ago. Stool screening for occult blood, barium enema roentgenographic examination, and colonoscopy become more important diagnostic tools in light of this trend. (<i>JAMA</i>238:1641-1643, 1977)